This system includes cardiovascular toxicity based on patient baseline characteristics, such as age, hypertension, chronic kidney disease, proteinuria, diabetes, dyslipidemia, history of previous cardiovascular disease (CVD), electrocardiography, TTE assessment (LVEF, LV hypertrophy), and cardiac serum biomarkers including cardiac troponin (cTn) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The gene discussed is NPPB; the disease is Hypertension.